Perfusion-Based Antibody Production in the Ambr 250 Modular.

Chimia (Aarau)

ZHAW Zurich University of Applied Sciences, School of Life Sciences and Facility Management, CH-8820 Wädenswil, Switzerland.

Published: May 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The perfusion mode has become increasingly important in biopharmaceutical production in recent years. A bioreactor system used in many laboratories for the development of monoclonal antibodies (mAbs) production processes is the Sartorius' Ambr. 250 system. Vessels designed for perfusion mode are only available for its high throughput version, while the modular version of the Ambr 250 is not designed for perfusion mode. In this study, perfusion processes for the production of a mAb with Chinese Hamster Ovary (CHO) cells were realized in the Ambr 250 Modular in combination with Repligen's ATF 1 single-use device for the first time, to the authors' knowledge. After testing a semi-perfusion setup in well plates and the Ambr 250, an N-1 perfusion process was developed to produce ultra-high cell densities of more than 150 Å~ 106 cells mL-1 for the inoculation of subsequent mAb production processes. In a second step, continuous mAb production was successfully realized over 23 days in a proof-of-concept experiment, achieving a volumetric productivity of 0.65 g L-1 d-1. The results of the N-1 and continuous perfusion processes were comparable to a 3 L HyPerformaTM Glass bioreactor (Thermo Scientific) with an ATF 2 (Repligen).

Download full-text PDF

Source
http://dx.doi.org/10.2533/chimia.2025.330DOI Listing

Publication Analysis

Top Keywords

ambr 250
20
perfusion mode
12
250 modular
8
production processes
8
designed perfusion
8
perfusion processes
8
mab production
8
production
6
perfusion
6
ambr
5

Similar Publications

Process mapping and optimization study of CHO cell cultures for mAb production using Ambr 250 high-throughput parallel bioreactors.

Bioprocess Biosyst Eng

August 2025

Department of Sustainable Chemical, Biological and Materials Engineering, University of Oklahoma, Norman, 73019, USA.

The demand to accelerate monoclonal antibody (mAbs) process development timelines using Chinese hamster ovary (CHO) host cells to bring therapies to patients sooner is gaining momentum. The applicability of single use high-throughput (HTP) bioreactor system such as Ambr250 facilitating precise and automated control is very promising. This entails optimizing process parameters through design of experiments (DoE) using less resources and time, compared to traditionally employed large-scale bench top reactors (2-5L).

View Article and Find Full Text PDF

The expansion of autologous chimeric antigen receptor (CAR) T cells to reach a therapeutic dose significantly prolongs manufacturing time and increases overall costs. The common use of animal- or human-derived serum in T cell expansion culture media further contributes to process variability, costs and introduces additional safety concerns. To address these challenges, this study focused on intensifying CAR-T cell expansion using perfusion processes in xeno-free (XF) and serum-free (SF) culture medium.

View Article and Find Full Text PDF

Perfusion-Based Antibody Production in the Ambr 250 Modular.

Chimia (Aarau)

May 2025

ZHAW Zurich University of Applied Sciences, School of Life Sciences and Facility Management, CH-8820 Wädenswil, Switzerland.

The perfusion mode has become increasingly important in biopharmaceutical production in recent years. A bioreactor system used in many laboratories for the development of monoclonal antibodies (mAbs) production processes is the Sartorius' Ambr. 250 system.

View Article and Find Full Text PDF

Chimeric antigen receptor T cell (CAR-T) therapies show high remission rates for relapsed and refractory leukemia and lymphoma. However, manufacturing challenges hinder their commercial viability and patient accessibility. This study applied quality-by-design principles to identify perfusion critical process parameters for CAR-T expansion in stirred tank bioreactors to maximize yields.

View Article and Find Full Text PDF

Process intensification has become an important strategy to lower production costs and increase manufacturing capacities for biopharmaceutical products. In particular for the production of viral vectors like lentiviruses (LVs), the transition from (fed-)batch to perfusion processes is a key strategy to meet the increasing demands for cell and gene therapy applications. However, perfusion processes are associated with higher medium consumption.

View Article and Find Full Text PDF